middle.news
How Will Syntara’s SNT-5505 Fast Track Status Transform Myelofibrosis Care?
9:15am on Tuesday 10th of June, 2025 AEST
•
Healthcare
Read Story
How Will Syntara’s SNT-5505 Fast Track Status Transform Myelofibrosis Care?
9:15am on Tuesday 10th of June, 2025 AEST
Key Points
FDA Fast Track designation granted for SNT-5505
Targets myelofibrosis patients with inadequate response to JAK inhibitors
Potential for accelerated approval and priority review
Phase 2 clinical trial ongoing with interim data due mid-June
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Syntara (ASX:SNT)
OPEN ARTICLE